Show simple item record

dc.contributor.authorMartinez-Lage, Marta
dc.contributor.authorPuig-Serra, Pilar
dc.contributor.authorMenendez, Pablo
dc.contributor.authorTorres-Ruiz Raul, Raul 
dc.contributor.authorRodriguez Perales, Sandra 
dc.date.accessioned2019-09-24T09:13:16Z
dc.date.available2019-09-24T09:13:16Z
dc.date.issued2018-11-12
dc.identifier.citationBiomedicines. 2018 ;6(4). pii: E105es_ES
dc.identifier.issn2227-9059es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8369
dc.description.abstractCancer is the second leading cause of death globally and remains a major economic and social burden. Although our understanding of cancer at the molecular level continues to improve, more effort is needed to develop new therapeutic tools and approaches exploiting these advances. Because of its high efficiency and accuracy, the CRISPR-Cas9 genome editing technique has recently emerged as a potentially powerful tool in the arsenal of cancer therapy. Among its many applications, CRISPR-Cas9 has shown an unprecedented clinical potential to discover novel targets for cancer therapy and to dissect chemical-genetic interactions, providing insight into how tumours respond to drug treatment. Moreover, CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications. Perhaps more importantly, the ability of CRISPR-Cas9 to accurately edit genes, not only in cell culture models and model organisms but also in humans, allows its use in therapeutic explorations. In this review, we discuss important considerations for the use of CRISPR/Cas9 in therapeutic settings and major challenges that will need to be addressed prior to its clinical translation for a complex and polygenic disease such as cancer.es_ES
dc.description.sponsorshipThis work was supported by funds from the Spanish National Research and Development Plan, Instituto de Salud Carlos III and FEDER (PI17/02303 to S.R-P). RTR is supported by a postdoctoral fellowship from the AECC scientific foundation.es_ES
dc.language.isoenges_ES
dc.publisherMPDIes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectCRISPRes_ES
dc.subjectCas9es_ES
dc.subjectadvance therapyes_ES
dc.subjectcancer modelses_ES
dc.subjectgenome engineeringes_ES
dc.titleCRISPR/Cas9 for Cancer Therapy: Hopes and Challengeses_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID30424477es_ES
dc.format.volume6es_ES
dc.format.number4es_ES
dc.format.page105es_ES
dc.identifier.doi10.3390/biomedicines6040105es_ES
dc.contributor.funderAsociación Española Contra el Cáncer
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/biomedicines6040105.es_ES
dc.identifier.journalBiomedicineses_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Citogenética Moleculares_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/02303es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional